Rebalix
LGIM · sheet of 10 September 2026
LGIM · sheet of 10 September 2026ETF sheet · official issuer and register data
L&G Healthcare Technology & Innovation UCITS ETF
DOCT · IE00BK5BC677 · class USD Acc. · USD · domicile Ireland
Equity · Global · Health care · ThematicSFDR art. 9
Index tracked: ROBO Global® Healthcare Technology and Innovation Index TR
- TER
- 0.49%+ trans. 0.07%
- Fund size
- 227 m EUR
- Tracking difference
- −0.65%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical (full replication)
- Income
- Accumulating
Launch 2 Jul 2019 · costs from the KID as of 2 Sept 2026 · 0 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund is passively managed and aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”), before the deduction of fees and expenses. The Index is designed to provide exposure to global companies that are involved in the healthcare technology and innovation industry, in accordance with its methodology.
The Fund seeks to achieve its investment objective by investing primarily in equity securities…
Performance since series start (in euro) — base 100
25 Jun 2019 → 31 Jul 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +35.9% |
| 3 years | +22.2% |
| 5 years | −14.1% |
| 10 years | series too young |
| Since series start | +62.0% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 20.91% | 20.62% | 23.59% |
| Max drawdown | −16.82% | −22.73% | −55.00% |
| Sharpe | 1.46 | 0.64 | -0.11 |
| Sortino | 2.44 | 0.97 | -0.16 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · DOCT · IE00BK5BC6771
RebalixDOCT · IE00BK5BC677 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +24.27% | +24.85% | −0.59% |
| 2024 | +3.07% | +3.53% | −0.46% |
| 2023 | −2.83% | −1.94% | −0.89% |
| 2022 | −33.34% | −33.15% | −0.19% |
| 2021 | +0.15% | +0.33% | −0.18% |
Holdings
Portfolio as declared by the issuer · 30 Jun 2026 · 0 securities · top-10 weight = 22.1%
| Top holdings | Weight |
|---|---|
| 2.7% | |
| 2.3% | |
| 2.2% | |
| 2.2% | |
| 2.2% | |
| 2.1% | |
| 2.1% | |
| 2.1% | |
| 2.1% | |
| 2.1% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
DOCT · Borsa Italiana (ETFplus)
XMLH · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 15 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BK5BC677
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BK5BC677
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · DOCT · IE00BK5BC6772